Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
Zacks Investment Research | Nov 01, 2017 12:05AM ET
Aduro BioTech, Inc. (NASDAQ:ADRO) reported third-quarter 2017 loss of 33 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 54 cents per share.
Quarterly revenues fell 2.4% year over year to $3.7 million. The top line also missed the Zacks Consensus Estimate of $4.18 million. In July, the company recognized a milestone payment of $2 million from Merck & Co (NYSE:MRK) related to development of Aduro’s anti-CD27 antibody.
Aduro’s shares have underperformed the industry so far this year. The stock has declined 30.3% while the industry registered an increase of 3.3%.
Research and development expenses showed a substantial increase of 28.4% in the quarter to $24.5 million, mainly due to an increase in costs related to manufacturing of B-select antibodies and higher facility related costs.
General and administrative expenses were $8.5 million, down 1.1% year over year due to lower consulting and professional fees.
Pipeline Update
Aduro has a broad pipeline of novel immunotherapies under development for the treatment of a variety of cancers.
The company initiated a phase I study in September to evaluate personalized live, attenuated double-deleted Listeria monocytogenes (pLADD)-based immunotherapy. The immunotherapy, which uses patient-specific antigens, will be studied in patients with microsatellite stable metastatic colorectal cancer. Aduro’s most advanced LADD candidate, CRS-207, is being evaluated in combination with Bristol-Myers Squibb Company’s (NYSE:BMY) Opdivo in two separate phase II studies for gastric cancer and mesothelioma. Data from mesothelioma study is expected by the end of this year.
Meanwhile, the company initiated a phase Ib study to evaluate its STING pathway activator, ADU-S100, in combination with Novartis AG’s (NYSE:NVS) PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
During the quarter, Aduro announced that the FDA has cleared the investigational new drug application ("IND") for anti-APRIL antibody, BION-1301. The company expects to initiate a phase I study by 2017.
Aduro Biotech, Inc. Price, Consensus and EPS Surprise
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.